Table 2.
Subgroup Analyses of Cross-Sectional Associations Between HIV Status and Frailty
| Variables | Number of Cohorts | Pooled Prevalence (95% CI) | P for Heterogeneity | I2 |
|---|---|---|---|---|
| Total | 26 | 10.9 (8.1–14.2) | <.001 | 93% |
| Subgroup | ||||
| Mean/Median Age | ||||
| <55 | 11 | 10.2 (5.7–15.8) | <.001 | 96% |
| >55 | 10 | 12.2 (7.8–17.5) | <.001 | 88% |
| Female Sex (%) | ||||
| 0–36 | 19 | 11.2 (7.8–15.2) | <.001 | 94% |
| 50–100 | 3 | 10.0 (3.9–18.6) | <.01 | 79% |
| Location | ||||
| US/Canada | 16 | 12.5 (8.1–17.6) | <.001 | 95% |
| Europe | 5 | 9.0 (6.4–12.0) | .02 | 68% |
| Asia/others | 5 | 8.5 (3.4–15.4) | <.001 | 89% |
| Frailty Assessment Year | ||||
| 2003–2014 | 11 | 11.5 (6.7–17.4) | <.001 | 96% |
| 2015–2018 | 11 | 10.0 (6.3–14.6) | <.001 | 90% |
| Current CD4 (Cells/μL) | ||||
| 466–574 | 9 | 14.0 (8.6–20.6) | <.001 | 94% |
| 592–673 | 9 | 11.3 (7.8–15.4) | <.001 | 80% |
| Nadir CD4 (Cells/μL) | ||||
| 50–159 | 7 | 11.4 (6.4–17.6) | < 0.001 | 91% |
| 161–208 | 7 | 11.7 (8.7–15.0) | 0.02 | 60% |
| Undetectable VL (%) | ||||
| 69.5–92.6 | 10 | 11.7 (6.4–18.4) | < 0.001 | 97% |
| 93.3–100 | 9 | 10.1 (7.3–13.3) | < 0.001 | 74% |
| Years Since HIV Diagnosis | ||||
| 11.1–17.5 | 7 | 12.5 (7.6–18.3) | < 0.001 | 85% |
| 19.1–23.2 | 6 | 9.7 (7.7–12.0) | 0.66 | 0% |
| Treatment Duration (Years) | ||||
| 2.2–10.0 | 4 | 14.6 (5.0–28.0) | < 0.001 | 98% |
| 11.3–18.3 | 4 | 12.5 (6.5–20.0) | < 0.001 | 85% |
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; VL, viral load.